Drug Profile
Gacyclidine intratympanic controlled release - Otonomy
Alternative Names: GK-11; OTO 311; OTO 313Latest Information Update: 25 Nov 2022
Price :
$50
*
At a glance
- Originator Otonomy
- Class Cyclohexanes; Neuroprotectants; Piperidines; Small molecules; Thiophenes
- Mechanism of Action NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Tinnitus
Most Recent Events
- 18 Nov 2022 Otonomy withdraws a phase III trial in Tinnitus due to the discontinuation of the development of OTO 313 (Intratympanic)
- 01 Aug 2022 Discontinued - Phase-II for Tinnitus in USA, Germany, Poland, United Kingdom (Intratympanic)
- 01 Aug 2022 Efficacy data from a phase II trial in Tinnitus released by Otonomy